OCT Evaluation of Neovascular AMD in Clinical Trials:
A Reading Center Perspective
This webinar video provides an overview of the role a reading center plays in the use of Optical Coherence Tomography (OCT) in major studies for patients with neovascular Age-related Macular Degeneration (nAMD). MERIT experts review the capabilities of the reading center and summarize how these studies are approached.
3 key questions that are answered:
- What benefits does a reading center offer Sponsors pursuing nAMD studies with OCT endpoints?
- What are the common inclusion/exclusion eligibility criteria for OCT in nAMD studies?
- Which OCT endpoints are often used for nAMD studies?
Amanda WeberPARTNERSHIPS MANAGER
In her role as Partnerships Manager at MERIT, Amanda serves as a primary point of contact for many valued CRO partners and Sponsors. Amanda is dedicated to providing timely communication and support to both current and prospective clients throughout the entire pre-award process. She has over 15 years of experience in account management and client service.
Dr. Wilker is the current medical director of ophthalmology at MERIT. He is board-certified in ophthalmology and is a retinal specialist with over 15 years of clinical experience. At MERIT, he spearheads the development of evaluation procedures for ophthalmic imaging grading. Dr. Wilker’s roles include analyzing and reading images and/or data for ophthalmic clinical trials, performing reading quality control tasks, developing analysis and reading procedures for ophthalmic clinical trials, and providing training for readers. Dr. Wilker currently practices in Cleveland, OH.